Publications by authors named "Udai Banerji"

90Publications

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.

Lancet Oncol 2020 07;21(7):889-891

Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30339-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324104PMC
July 2020

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer.

Mol Cancer Ther 2020 07 5;19(7):1423-1435. Epub 2020 May 5.

Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-1131DOI Listing
July 2020

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.

Clin Cancer Res 2020 Sep 24;26(18):4805-4813. Epub 2020 Apr 24.

Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0454DOI Listing
September 2020

Exploiting the folate receptor α in oncology.

Nat Rev Clin Oncol 2020 06 9;17(6):349-359. Epub 2020 Mar 9.

The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-020-0339-5DOI Listing
June 2020

Inactivation of Promotes Resistance to EGFR Inhibition in -Wild-Type Colorectal Cancer.

Mol Cancer Res 2020 06 25;18(6):835-846. Epub 2020 Feb 25.

Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-19-1201DOI Listing
June 2020

The kinase polypharmacology landscape of clinical PARP inhibitors.

Sci Rep 2020 02 17;10(1):2585. Epub 2020 Feb 17.

Department of Data Science, The Institute of Cancer Research, London, SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-59074-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026418PMC
February 2020

Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp.

Eur J Cancer 2019 11 7;122:9-11. Epub 2019 Oct 7.

Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, London, SM2 5PT, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.08.023DOI Listing
November 2019

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.

Eur J Cancer 2018 11 10;104:32-38. Epub 2018 Oct 10.

The Royal Marsden NHS Foundation Trust, Downs Rd, Sutton, SM2 5PT, London, UK; The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, London, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183133
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.08.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259582PMC
November 2018

Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.

Cancer Chemother Pharmacol 2018 Nov;82(5):911-912

Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3674-9DOI Listing
November 2018

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

J Neurooncol 2018 Aug 10;139(1):107-116. Epub 2018 Apr 10.

Drug Development Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2847-zDOI Listing
August 2018

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

Eur J Cancer 2018 05 31;95:20-29. Epub 2018 Mar 31.

Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK; Gynaecology Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.02.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296443PMC
May 2018

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.

Oncotarget 2017 Dec 6;8(69):113874-113884. Epub 2017 Dec 6.

Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research and The Royal Marsden, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768370PMC
December 2017

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Lung Cancer 2017 09 15;111:6-11. Epub 2017 Jun 15.

Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.06.005DOI Listing
September 2017

Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein Quantification.

Methods Mol Biol 2017 ;1636:119-131

The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7154-1_9DOI Listing
April 2018

Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.

Bioanalysis 2017 Jul 10;9(13):1001-1010. Epub 2017 Jul 10.

Newcastle Cancer Centre Pharmacology Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH2, UK.

View Article

Download full-text PDF

Source
http://www.future-science.com/doi/10.4155/bio-2017-0043
Publisher Site
http://dx.doi.org/10.4155/bio-2017-0043DOI Listing
July 2017

AKT Inhibition in Solid Tumors With AKT1 Mutations.

J Clin Oncol 2017 Jul 10;35(20):2251-2259. Epub 2017 May 10.

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue, Matthew T. Chang, Jonathan B. Reichel, Nancy Bouvier, S. Duygu Selcuklu, Tara E. Soumerai, Jean Torrisi, Joseph P. Erinjeri, Michael F. Berger, Sarat Chandarlapaty, David B. Solit, José Baselga, and Barry S. Taylor, Memorial Sloan Kettering Cancer Center; David B. Solit, Weill Cornell Medical College, Cornell University, New York, NY; J. Carl Barrett and Brian Dougherty, AstraZeneca, Waltham, MA; Helen Ambrose, Andrew Foxley, Justin P.O. Lindemann, Robert McEwen, Martin Pass, and Gaia Schiavon, AstraZeneca, Cambridge; Emma J. Dean, The Christie National Health Service Foundation, Manchester; Udai Banerji, Royal Marsden Hospital, London, United Kingdom; Shannon N. Westin, The University of Texas MD Anderson Cancer Center, Houston, TX; Philippe L. Bedard, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Hideaki Bando, National Cancer Center East Hospital, Kashiwa, Japan; Anthony B. El-Khoueiry, University of Southern California Norris Comprehensive Cancer Center; Alain Mita, Cedars-Sinai Medical Center, Los Angeles, CA; José A. Pérez-Fidalgo, Hospital Clinico de Valencia, Valencia, Spain; and Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.0143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501365PMC
July 2017

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

Mol Oncol 2017 08 31;11(8):996-1006. Epub 2017 May 31.

Paediatric Solid Tumour Biology and Therapeutics Team, Division of Clinical Studies and Cancer Therapeutics Division, The Institute of Cancer Research, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/1878-0261.12069
Publisher Site
http://dx.doi.org/10.1002/1878-0261.12069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537911PMC
August 2017

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

Eur J Cancer 2017 05 6;76:52-59. Epub 2017 Mar 6.

Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK; The Institute of Cancer Research, Cotswold Road, London SM2 5NG, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.020DOI Listing
May 2017

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.

J Clin Oncol 2017 Apr 27;35(12):1304-1311. Epub 2017 Feb 27.

Andrew J. Wagner, Dana-Farber Cancer Institute, Boston, MA; Udai Banerji, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Amit Mahipal, Moffitt Cancer Center, Tampa, FL; Neeta Somaiah and David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX; and Heather Hirsch, Craig Fancourt, Amy O. Johnson-Levonas, Raymond Lam, Amy K. Meister, Giuseppe Russo, Clayton D. Knox, and Shelonitda Rose, Merck & Co., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946729PMC
April 2017

Maximising the potential of AKT inhibitors as anti-cancer treatments.

Pharmacol Ther 2017 Apr 3;172:101-115. Epub 2016 Dec 3.

Royal Marsden NHS Foundation Trust, London SM2 5PT, UK; The Institute of Cancer Research, London SM2 5NG, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2016.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143165PMC
April 2017

Combine and conquer: challenges for targeted therapy combinations in early phase trials.

Nat Rev Clin Oncol 2017 Jan 5;14(1):57-66. Epub 2016 Jul 5.

Drug Development Unit, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, London SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.96DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135233PMC
January 2017

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Eur J Cancer 2016 11 28;68:1-10. Epub 2016 Sep 28.

Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; Northern Centre for Cancer Care, Newcastle Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.08.026DOI Listing
November 2016

Critical parameters in targeted drug development: the pharmacological audit trail.

Semin Oncol 2016 08 14;43(4):436-45. Epub 2016 Jun 14.

Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.06.001DOI Listing
August 2016

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer.

Br J Cancer 2016 08 21;115(5):549-52. Epub 2016 Jul 21.

The Institute of Cancer Research, Clinical Pharmacology and Trials Team, London, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997545PMC
August 2016

Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development.

J Clin Oncol 2016 07 2;34(20):2431-2. Epub 2016 May 2.

The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.0075DOI Listing
July 2016

Antibody-drug conjugates--an emerging class of cancer treatment.

Br J Cancer 2016 Feb 7;114(4):362-7. Epub 2016 Jan 7.

Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, Downs Road, Sutton, London SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2015.435DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815767PMC
February 2016

Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?

Clin Cancer Res 2016 05 18;22(9):2127-32. Epub 2015 Nov 18.

The Institute of Cancer Research, London, United Kingdom. The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1855DOI Listing
May 2016

Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.

Oncology 2015 28;89(1):53-9. Epub 2015 Feb 28.

Oncology Unit, 2nd Department of Internal Medicine, University General Hospital 'Attikon', Athens, Greece.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/371711
Publisher Site
http://dx.doi.org/10.1159/000371711DOI Listing
September 2015

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

Clin Cancer Res 2015 Apr 3;21(8):1869-76. Epub 2015 Feb 3.

Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research and The Royal Marsden, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401558PMC
April 2015

A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors.

Clin Cancer Res 2014 Jan 4;20(2):445-55. Epub 2013 Oct 4.

Authors' Affiliations: Tufts University School of Medicine, Boston, Massachusetts; Institute for Drug Development Cancer Therapy and Research Center, San Antonio, Texas; Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, New York; University of California San Diego; Biogen Indec, San Diego, California; University of Texas M.D. Anderson Cancer Center, Houston, Texas; and TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1257DOI Listing
January 2014

Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

Cancer Treat Rev 2013 Jun 28;39(4):375-87. Epub 2012 Nov 28.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2012.10.001DOI Listing
June 2013

Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Curr Drug Targets 2012 Nov;13(12):1525-34

The Institute of Cancer Research, Sutton, UK.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531821PMC
http://dx.doi.org/10.2174/138945012803530062DOI Listing
November 2012

Combinatorial drug therapy for cancer in the post-genomic era.

Nat Biotechnol 2012 Jul 10;30(7):679-92. Epub 2012 Jul 10.

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt.2284DOI Listing
July 2012

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

Mol Cancer Ther 2012 Jul 3;11(7):1609-17. Epub 2012 May 3.

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutic, The Institute of Cancer Research, Sutton,United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0996DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630857PMC
July 2012

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.

Clin Cancer Res 2012 May;18(9):2687-94

The Drug Development Unit, Sycamore House, Division of Cancer Therapeutics/Division of Clinical Studies, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-3165DOI Listing
May 2012

Revisiting the role of molecular targeted therapies in patients with brain metastases.

J Neurooncol 2011 Dec 22;105(3):467-74. Epub 2011 Jul 22.

Royal Marsden Hospital, Sutton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-011-0661-yDOI Listing
December 2011

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

Invest New Drugs 2012 Feb 5;30(1):341-9. Epub 2010 Aug 5.

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-010-9493-4
Publisher Site
http://dx.doi.org/10.1007/s10637-010-9493-4DOI Listing
February 2012

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Cancer J 2009 Sep-Oct;15(5):406-20

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2009/10000/Biomarker
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0b013e3181bd0445DOI Listing
April 2010

Heat shock protein 90 as a drug target: some like it hot.

Authors:
Udai Banerji

Clin Cancer Res 2009 Jan;15(1):9-14

Section of Medicine, The Royal Marsden Hospital/The Institute of Cancer Research, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-0132DOI Listing
January 2009

Biomarkers in early clinical trials: the committed and the skeptics.

Clin Cancer Res 2008 Apr;14(8):2512; author reply 2513-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-5224DOI Listing
April 2008

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.

Mol Cancer Ther 2008 Apr 28;7(4):737-9. Epub 2008 Mar 28.

Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0145DOI Listing
April 2008

An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.

Cancer Chemother Pharmacol 2008 Oct 10;62(5):769-78. Epub 2008 Jan 10.

Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0662-xDOI Listing
October 2008

Factors determining outcome after third line chemotherapy for metastatic breast cancer.

Breast 2007 Aug 16;16(4):359-66. Epub 2007 May 16.

The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2007.01.004DOI Listing
August 2007

The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer.

Lung Cancer 2006 Dec 17;54(3):371-7. Epub 2006 Oct 17.

The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2006.08.001DOI Listing
December 2006

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.

Clin Cancer Res 2005 Oct;11(19 Pt 1):7023-32

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0518DOI Listing
October 2005

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.

J Natl Cancer Inst 2003 Nov;95(21):1624-33

Cancer Research UK Biomedical Magnetic Resonance Research Group, Department of Basic Medical Sciences, St. George's Hospital Medical School, London, UK.

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/95/21/1624.full.pdf
Web Search
http://dx.doi.org/10.1093/jnci/djg084DOI Listing
November 2003

The clinical applications of heat shock protein inhibitors in cancer - present and future.

Curr Cancer Drug Targets 2003 Oct;3(5):385-90

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009033481813DOI Listing
October 2003